Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 9 de 9 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
D'Silva M, Hallas J, Pottegård A, Kristiansen NS, Atsma WJ, Franks B, D'Silva M, Varas-Lorenzo C, Perez-Gutthann S, Arana J. Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study. Eur J Clin Pharmacol 2018;74:febrero. [Ref.ID 102545]
2. Cita con resumen
Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzlez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf 2017;26:615-24. [Ref.ID 101961]
3.Tiene citas relacionadas Cita con resumen
Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, on behalf of the Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857. [Ref.ID 100756]
4. Cita con resumen
Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013;22:559-70. [Ref.ID 95560]
5. Cita con resumen
Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S, on behalf of the investigators of the Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS) Project). Drug Saf 2012;35:1127-46. [Ref.ID 94171]
6.Enlace a cita original Cita con resumen
Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenbbom M, Perez-Gutthann S. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011;20:1225-36. [Ref.ID 91664]
7.Enlace a cita originalTiene citas relacionadas
Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, García Rodríguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 2009;18:1016-25. [Ref.ID 87048]
8. Cita con resumen
Varas-Lorenzo C, Maguire A, Castellsagué J, Pérez-Gutthann S. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiol Drug Saf 2007;16:366-76. [Ref.ID 79962]
9. Cita con resumen
Varas-Lorenzo C, García-Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Pérez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in Southern Europe. Am J Epidemiol 1998;147:387-90. [Ref.ID 38083]
Seleccionar todas
 
 1 a 9 de 9